title: Treatment of acute myelogenous leukemia with outpatient azacitidine.
abstract: BACKGROUND
  Patients older than 55 years of age with acute myelogenous leukemia (AML) are less likely to achieve complete remission and more likely to experience toxicity with conventional induction chemotherapy than younger patients. Azacitidine administered in the outpatient setting is well tolerated and can induce complete hematological remission in patients with myelodysplastic syndromes (MDS). At higher doses, azacitidine has activity in AML.
  
  
  METHODS
  Twenty patients were retrospectively identified who had been treated with azacitidine with bone marrow blast counts between 21 and 38%. Patients with blast counts up to 29% were initially treated as MDS, but by WHO now meet criteria for AML. Patients with blast counts over 29% were treated with azacitidine after being deemed poor candidates for induction chemotherapy. Azacitidine 75 mg/m2/day was administered subcutaneously for 7 days every 4 weeks, which was defined as 1 cycle.
  
  
  RESULTS
  The overall response rate was 60% (12/20): complete response (CR; n = 4; 20%); partial response (PR; n = 5; 25%); hematologic improvement (HI; n = 3; 15%). The median survival of responders was 15+ months compared with 2.5 months for nonresponders (P = .009). During therapy, responders had an Eastern Cooperative Oncology Group (ECOG) performance status of 1 or 0. The most common toxic event was infection (n = 8). Four patients were hospitalized during the first cycle of treatment.
  
  
  CONCLUSIONS
  Azacitidine administered in the outpatient setting can induce remission in AML. The therapy is well tolerated and might be an alternative for patients unlikely to tolerate standard induction chemotherapy.
authors.affiliation: Division of Hematology/Oncology, Western Pennsylvania Cancer Institute, Pittsburgh, Pennsylvania 15224, USA.
authors.forename: Nimit
authors.initials: N
authors.lastname: Sudan
authors.forename: James M
authors.initials: JM
authors.lastname: Rossetti
authors.forename: Richard K
authors.initials: RK
authors.lastname: Shadduck
authors.forename: Joan
authors.initials: J
authors.lastname: Latsko
authors.forename: John A
authors.initials: JA
authors.lastname: Lech
authors.forename: Robert B
authors.initials: RB
authors.lastname: Kaplan
authors.forename: Margaret
authors.initials: M
authors.lastname: Kennedy
authors.forename: Jeffrey F
authors.initials: JF
authors.lastname: Gryn
authors.forename: Yacoub
authors.initials: Y
authors.lastname: Faroun
authors.forename: John
authors.initials: J
authors.lastname: Lister
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D001374:Azacitidine / Q000008:administration & dosage*; D001853:Bone Marrow / Q000473:pathology; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D007951:Leukemia, Myeloid / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010045:Outpatients; D012189:Retrospective Studies
chemical_list: D000964:Antimetabolites, Antineoplastic; D001374:Azacitidine